Esperion Therapeutics (NASDAQ: ESPR) disclosed that President and Chief Executive Officer Sheldon L. Koenig sold 25,578 shares of the company's common stock on March 17, 2026. The shares were disposed of at $2.719 per share, resulting in a total transaction value of $69,546, according to the SEC filing.
Following the sale, Koenig retains direct ownership of 2,172,699 shares of Esperion. A footnote in the filing states the stock sale was completed to satisfy tax obligations associated with vested restricted stock units.
The market price for Esperion shares stood at $2.50 at the time of this report, down from a previous close of $2.69. Over the prior 12 months the shares had returned 71.52 percent, while they were down 26.76 percent year-to-date.
Although Esperion was not profitable over the last twelve months, analysis cited in the company s investor information indicates analysts expect the company to reach profitability in the current fiscal year, with forecasted earnings of $0.09 per share for fiscal 2026. The company carries a market capitalization of $648 million.
In operational results disclosed for the fourth quarter of 2025, Esperion reported earnings per share of $0.22, which missed the consensus forecast of $0.29. Revenue for the quarter was $168.45 million, a figure that slightly exceeded expectations and represented a 144 percent increase from the year-ago quarter.
Separately, Esperion announced that bempedoic acid received multiple Class 1 recommendations in the 2026 guidelines issued by the American College of Cardiology and the American Heart Association for the management of dyslipidemia. Those recommendations endorse the use of bempedoic acid for adults with statin intolerance who are at high cardiovascular risk.
Analyst coverage of Esperion shows a range of views. H.C. Wainwright reiterated a Buy rating and set a $16 price target, citing the company s commercial approach and international footprint. Citizens raised its price target to $5.00 from $4.00, highlighting projected growth for NEXLETOL and NEXLIZET. By contrast, BofA Securities maintained an Underperform rating with a $1.78 target.
The SEC filing makes clear the recent insider sale was motivated by tax requirements tied to equity vesting rather than an open-market personal investment decision. At the same time, company performance and external endorsements for its lead therapeutic have produced mixed signals for investors and analysts.
Below are concise takeaways and considerations drawn from the filings, financial results, and analyst commentary disclosed publicly by the company.